Jay Herath/loyno.edu
Mar 24, 2026, 02:50
Jay Herath: Fitusiran Advancing Hemophilia Care Beyond Factor Replacement
Jay Herath, Professor of the Practice at Loyola University, shared a post on LinkedIn:
“Qfitlia (fitusiran), approved in 2025, is a first-in-class siRNA therapy that treats hemophilia A and B by targeting antithrombin-III mRNA in the liver.
Instead of replacing missing clotting factors (Factor VIII or IX), it reduces antithrombin levels, restoring the body’s ability to generate thrombin and form stable blood clots.”
Stay updated with Hemostasis Today.
-
Apr 18, 2026, 11:33Standing Together for Patients with Bleeding Disorders – ISTH
-
Apr 18, 2026, 11:21Gianluca Franceschini: Immersive Virtual Reality in Preoperative Care
-
Apr 18, 2026, 10:58Jean Jacques Kiladjian: Honored to Join the HST EHA Session at the Taiwan Annual Meeting
-
Apr 18, 2026, 10:49Advancing Diagnosis to Improve Lives in Hemophilia – WFH
-
Apr 18, 2026, 10:40Akshat Jain: Improving Treatment and Access for Patients with Bleeding Disorders
-
Apr 18, 2026, 10:24Sonia Wolf: Barts Health Presence at BSH with Multiple Presentations and Awards
-
Apr 18, 2026, 10:22Cathy Harrison: The Central Role of Diagnosis in Bleeding Disorders Management
-
Apr 18, 2026, 10:10Rich Gorman: Understanding Lived Experience in Bleeding Disorders Through Arts-Based Research
-
Apr 18, 2026, 09:45Wolfgang Miesbach: Therapeutic Potential of Protein S Inhibition in Glanzmann Thrombasthenia